Wang Q, Yang J H, Chen X, Zhang Y J, Zhu X Y, Li X F, Su J, Churangui C R G, Yang B, Lu G P, Xu Y
Department of Infectious Diseases, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510623, China.
Vision Medicals Co., Ltd., Guangzhou, Guangzhou 510700, China.
Zhonghua Er Ke Za Zhi. 2024 May 2;62(5):457-461. doi: 10.3760/cma.j.cn112140-20240105-00019.
To analyze the drug-resistant gene loci of (MP) using metagenomic next-generation sequencing (mNGS). From November 2022 to October 2023, 697 clinical samples (including sputum, alveolar lavage fluid and blood) of 686 children with positive detected by mNGS were retrospectively analyzed. Samples were divided into intensive care unit (ICU) group and non-ICU group, Chi-square test was used to compare groups, and Mann-Kendall trend test was used to analyze the change trend of the detection rate of drug resistance gene loci over time. Of the 697 samples, 164 were from the ICU group and 533 were from the non-ICU group. The detection rate of resistance gene was 44.3% (309/697), and all detected drug-resistant gene loci of MP were A2063G. The detection rate of in ICU group was 50.0% (82/164), and the detection rates of resistance gene loci in sputum, alveolus lavage fluid and blood samples were 75.0% (18/24) and 48.4% (62/128), respectively. The detection rate in sputum was higher than alveolus lavage fluid samples (=5.72,=0.017). The detection rate of in non-ICU group was 42.6% (227/533), the detection rate of resistance gene loci in sputum and alveolar lavage fluid was 40.0% (16/40), 44.3% (201/454), and no detection rate in blood samples (0/12). There was no significant difference in the detection rate of alveolar lavage fluid and sputum (=0.27, =0.602). From November 2022 to October 2023, the detection rate of submitted samples showed an increasing trend month by month (overall: =3.99, ICU inspection group: =2.93, non-ICU group: =3.01, all <0.01). Among the bacteria commonly detected with , Streptococcus pneumoniae accounted for the highest proportion, the detection rate was 15.5% (108/697), and Epstein-Barr virus accounted for the highest proportion of 17.6% (123/697). From November 2022 to October 2023, the detection rate of drug resistance gene loci showed an increasing trend. The detection rate of drug resistance gene loci in sputum samples of ICU group was higher than alveolus lavage fluid. No new drug resistance site were detected.
采用宏基因组二代测序(mNGS)分析肺炎支原体(MP)的耐药基因位点。回顾性分析2022年11月至2023年10月期间686例经mNGS检测MP阳性的儿童的697份临床样本(包括痰液、肺泡灌洗液和血液)。样本分为重症监护病房(ICU)组和非ICU组,采用卡方检验比较组间差异,采用曼-肯德尔趋势检验分析耐药基因位点检出率随时间的变化趋势。697份样本中,164份来自ICU组,533份来自非ICU组。MP耐药基因检出率为44.3%(309/697),所有检测到的MP耐药基因位点均为A2063G。ICU组检出率为50.0%(82/164),痰液、肺泡灌洗液和血液样本中MP耐药基因位点检出率分别为75.0%(18/24)和48.4%(62/128)。痰液中的检出率高于肺泡灌洗液样本(χ² =5.72,P =0.017)。非ICU组检出率为42.6%(227/533),痰液和肺泡灌洗液中MP耐药基因位点检出率分别为40.0%(16/40)、44.3%(201/454),血液样本未检出(0/12)。肺泡灌洗液和痰液检出率差异无统计学意义(χ² =0.27,P =0.602)。2022年11月至2023年10月,送检样本检出率呈逐月上升趋势(总体:Z =3.99,ICU检查组:Z =2.93,非ICU组:Z =3.01,均P <0.01)。在与MP共同检出的常见细菌中,肺炎链球菌占比最高,检出率为15.5%(108/697),EB病毒占比最高为17.6%(123/697)。2022年11月至2023年10月,MP耐药基因位点检出率呈上升趋势。ICU组痰液样本中耐药基因位点检出率高于肺泡灌洗液。未检测到新的耐药位点。